Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 22 days · First seen about 1 month ago · Last updated 11 days ago

Mesoblast Ryoncil commercial development

Overview

Mesoblast Limited has achieved regulatory and financial milestones regarding its Ryoncil product, an FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease.

In late September 2026, the U.S. Food and Drug Administration approved a new potency assay for Ryoncil known as the T-cell Proliferation Inhibition BioAssay (TIBA). This assay is intended to ensure consistent quality and potency during manufacturing scale-up and production changes.

By mid-October 2026, the company reported significant financial growth for the first fiscal quarter ending September 30, 2026. Mesoblast saw a 44% increase in net revenue from Ryoncil, totaling US$28 million, alongside an 85% improvement in net operating cash spend. The company noted a high number of new patient starts in September and plans to expand adoption across its 54 treatment sites.

Entities

Ryoncil · Mesoblast Limited · U.S. Food and Drug Administration · Silviu Itescu · Melbourne

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] Mesoblast reported its first fiscal quarter results for the period ending September 30, 2026.
[● 3 SOURCES] Net revenue from Ryoncil sales increased 44% to US$28 million compared to US$19 million in the prior year period.
[● 3 SOURCES] Net operating cash spend improved by 85%, reducing to US$2.3 million from US$14.9 million in the prior year period.
[● 3 SOURCES] The company recorded a cash position of US$99 million as of September 30, 2026.
[● 3 SOURCES] Ryoncil is the only FDA-approved mesenchymal stromal cell product for children under age 12 with steroid-refractory acute graft-versus-host disease.
[● 3 SOURCES] Ryoncil adoption is occurring across 54 onboarded treatment sites.

Timeline

11 days ago

[BUSINESS] 3 sources
Mesoblast reports 44% revenue surge in Ryoncil sales for Q1 FY26
Mesoblast reported a 44% increase in Ryoncil revenue to US$28 million and an 85% improvement in cash spend for Q1 FY26, ending the period with US$99 million in cash.
about 1 month ago

[HEALTH] 4 sources
Mesoblast secures FDA approval for new Ryoncil potency assay
Mesoblast has secured FDA approval for a new T-cell Proliferation Inhibition BioAssay (TIBA) to monitor the potency and stability of its Ryoncil cell therapy during commercial manufacturing.

Sources

finnewsnetwork.com.au · fool.com.au · mugglehead.com · sharecafe.com.au